Research Capital analyst Andre Uddin raised his target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD) to C$9.80 from C$8.55, maintaining a “Buy” rating in a May 7 report after what he called another strong quarter. Knight reported Q1 revenue of $148.4-million, up 69% year-over-year and ahead of Uddin’s $110.2-million estimate […]
National Bank Financial analyst Richard Tse maintained Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSX:KXS) as a Top Pick in a May 7 report after stronger-than-expected first-quarter results. “All in, Q1 showed execution on the efforts laid out over the past year and fortified by new strategic leadership,” Tse said. Kinaxis reported Q1 revenue […]
Share
Tweet
Share
